vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $180.9M, roughly 1.9× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -6.6%, a 5.9% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 0.7%). Westrock Coffee Co produced more free cash flow last quarter ($27.8M vs $21.3M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
AVNS vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $339.5M |
| Net Profit | $-1.3M | $-22.6M |
| Gross Margin | 47.5% | 11.5% |
| Operating Margin | 1.4% | -2.6% |
| Net Margin | -0.7% | -6.6% |
| Revenue YoY | 0.7% | 48.3% |
| Net Profit YoY | 99.7% | 8.3% |
| EPS (diluted) | $-0.02 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $339.5M | ||
| Q3 25 | $177.8M | $354.8M | ||
| Q2 25 | $175.0M | $280.9M | ||
| Q1 25 | $167.5M | $213.8M | ||
| Q4 24 | $179.6M | $229.0M | ||
| Q3 24 | $170.4M | $220.9M | ||
| Q2 24 | $171.7M | $208.4M | ||
| Q1 24 | $166.1M | $192.5M |
| Q4 25 | $-1.3M | $-22.6M | ||
| Q3 25 | $-1.4M | $-19.1M | ||
| Q2 25 | $-76.8M | $-21.6M | ||
| Q1 25 | $6.6M | $-27.2M | ||
| Q4 24 | $-397.3M | $-24.6M | ||
| Q3 24 | $4.3M | $-14.3M | ||
| Q2 24 | $1.8M | $-17.8M | ||
| Q1 24 | $-900.0K | $-23.7M |
| Q4 25 | 47.5% | 11.5% | ||
| Q3 25 | 48.4% | 11.7% | ||
| Q2 25 | 52.6% | 14.7% | ||
| Q1 25 | 53.6% | 13.6% | ||
| Q4 24 | 54.6% | 16.6% | ||
| Q3 24 | 54.5% | 16.8% | ||
| Q2 24 | 55.7% | 19.9% | ||
| Q1 24 | 57.1% | 19.4% |
| Q4 25 | 1.4% | -2.6% | ||
| Q3 25 | 0.1% | -2.4% | ||
| Q2 25 | -42.6% | -5.3% | ||
| Q1 25 | 6.1% | -6.1% | ||
| Q4 24 | -233.0% | -4.3% | ||
| Q3 24 | 7.0% | -5.8% | ||
| Q2 24 | 3.7% | -7.9% | ||
| Q1 24 | 2.4% | -5.3% |
| Q4 25 | -0.7% | -6.6% | ||
| Q3 25 | -0.8% | -5.4% | ||
| Q2 25 | -43.9% | -7.7% | ||
| Q1 25 | 3.9% | -12.7% | ||
| Q4 24 | -221.2% | -10.7% | ||
| Q3 24 | 2.5% | -6.5% | ||
| Q2 24 | 1.0% | -8.5% | ||
| Q1 24 | -0.5% | -12.3% |
| Q4 25 | $-0.02 | $-0.22 | ||
| Q3 25 | $-0.03 | $-0.20 | ||
| Q2 25 | $-1.66 | $-0.23 | ||
| Q1 25 | $0.14 | $-0.29 | ||
| Q4 24 | $-8.64 | $-0.26 | ||
| Q3 24 | $0.09 | $-0.16 | ||
| Q2 24 | $0.04 | $-0.20 | ||
| Q1 24 | $-0.02 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $49.9M |
| Total DebtLower is stronger | $90.3M | $444.1M |
| Stockholders' EquityBook value | $778.2M | $-1.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $49.9M | ||
| Q3 25 | $70.5M | $34.0M | ||
| Q2 25 | $90.3M | $44.0M | ||
| Q1 25 | $97.0M | $33.1M | ||
| Q4 24 | $107.7M | $26.2M | ||
| Q3 24 | $89.0M | $22.4M | ||
| Q2 24 | $92.2M | $24.3M | ||
| Q1 24 | $75.8M | $12.6M |
| Q4 25 | $90.3M | $444.1M | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $393.1M | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $-1.9M | ||
| Q3 25 | $778.0M | $11.4M | ||
| Q2 25 | $776.3M | $18.2M | ||
| Q1 25 | $839.4M | $71.4M | ||
| Q4 24 | $828.5M | $97.5M | ||
| Q3 24 | $1.2B | $110.3M | ||
| Q2 24 | $1.2B | $81.5M | ||
| Q1 24 | $1.2B | $91.7M |
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.1B | ||
| Q1 24 | $1.7B | $983.3M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 4.03× | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $36.7M |
| Free Cash FlowOCF − Capex | $21.3M | $27.8M |
| FCF MarginFCF / Revenue | 11.8% | 8.2% |
| Capex IntensityCapex / Revenue | 3.8% | 2.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $36.7M | ||
| Q3 25 | $14.0M | $-26.6M | ||
| Q2 25 | $6.8M | $-7.0M | ||
| Q1 25 | $25.7M | $-22.1M | ||
| Q4 24 | $57.9M | $2.8M | ||
| Q3 24 | $23.0M | $-332.0K | ||
| Q2 24 | $27.8M | $-23.7M | ||
| Q1 24 | $-8.0M | $8.0M |
| Q4 25 | $21.3M | $27.8M | ||
| Q3 25 | $7.0M | $-44.7M | ||
| Q2 25 | $-4.2M | $-27.5M | ||
| Q1 25 | $19.0M | $-63.4M | ||
| Q4 24 | $53.1M | $-15.4M | ||
| Q3 24 | $20.0M | $-36.7M | ||
| Q2 24 | $21.9M | $-59.9M | ||
| Q1 24 | $-12.1M | $-60.9M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 3.9% | -12.6% | ||
| Q2 25 | -2.4% | -9.8% | ||
| Q1 25 | 11.3% | -29.7% | ||
| Q4 24 | 29.6% | -6.7% | ||
| Q3 24 | 11.7% | -16.6% | ||
| Q2 24 | 12.8% | -28.7% | ||
| Q1 24 | -7.3% | -31.7% |
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 3.9% | 5.1% | ||
| Q2 25 | 6.3% | 7.3% | ||
| Q1 25 | 4.0% | 19.3% | ||
| Q4 24 | 2.7% | 7.9% | ||
| Q3 24 | 1.8% | 16.5% | ||
| Q2 24 | 3.4% | 17.4% | ||
| Q1 24 | 2.5% | 35.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
